Ionis Pharmaceuticals Faces Securities Fraud Investigation After Phase 3 CARDIO-TTRansform Trial Failure Sends Shares Down 23%
核心洞察
Ionis and AstraZeneca's Phase 3 CARDIO-TTRansform trial of eplontersen for ATTR cardiomyopathy failed to meet its primary efficacy endpoint, triggering a 23% single-day stock decline.
The trial revealed that over 80% of participants were on stabilizer therapy, a factor analysts cited as driving the primary endpoint failure.
Multiple shareholder rights firms, including Hagens Berman and Schall, Brown & Schwartz, have launched investigations into whether Ionis made misleading statements or failed to disclose material information.
Shares of Ionis Pharmaceuticals (搜索), Inc. (NASDAQ: IONS) plunged $20.19, or 23%, on July 9, 2026, after the company and its partner AstraZeneca announced that the Phase 3 CARDIO-TTRansform trial of eplontersen failed to meet its primary efficacy endpoint in patients with transthyretin amyloidosis cardiomyopathy (搜索) (ATTR-CM). The surprise result erased more than $3.3 billion in market capitalization and has now triggered securities fraud investigations by at least two national shareholder rights firms.
The CARDIO-TTRansform study, which completed enrollment in July 2023, was investigating eplontersen — also known as Wainua — as a treatment for ATTR-CM, a progressive and often fatal form of heart disease caused by the buildup of misfolded transthyretin (搜索) protein in cardiac tissue.
Trial Results and the Role of Background Stabilizer Therapy
In announcing the failure, Ionis stated that "in this contemporary patient population treated with standard of care, including a majority on a stabilizer, adding eplontersen did not provide a statistically significant benefit." The company further disclosed that 57% of patients in each arm received a stabilizer treatment at baseline, with an additional 24% in each arm initiating a stabilizer during the trial — meaning over 80% of participants were on stabilizer therapy.
One prominent analyst reportedly wrote: "Unbeknownst to us, > 80% of CARDIO-TTRansform participants were on stabilizer […] driving the failure of the primary endpoint."
Investor Scrutiny and Allegations of Inadequate Disclosure
The trial failure and subsequent market reaction have drawn sharp scrutiny from the investment community, particularly given the company's prior public statements about the study. Just weeks before the data readout, Ionis had touted the Phase 3 study as "the largest study ever conducted by far" in ATTR-CM, positioning the company for "the richest dataset for not only the primary endpoint, but the secondary endpoints." Ionis also assured investors that "everything is going very well in the conduct of the study and execution."
Hagens Berman, a national shareholders' rights firm, has opened an investigation into whether Ionis was sufficiently transparent about the trial's data and design and whether the company may have violated federal securities laws. Reed Kathrein, the Hagens Berman partner leading the investigation, stated: "Our investigation is focused on when Ionis and its management first knew about the apparent problems with the trial data or its design and whether they were sufficiently transparent to investors."
Separately, Schall, Brown & Schwartz LLP (SBS) announced its own investigation into claims on behalf of Ionis investors for potential violations of securities laws, focusing on whether the company issued false and/or misleading statements or failed to disclose information pertinent to investors.
Hagens Berman is encouraging whistleblowers with non-public information regarding Ionis to consider their options under the SEC Whistleblower program, which allows individuals who provide original information to receive rewards totaling up to 30% of any successful recovery made by the SEC.